Advanced searches left 3/3

Carboplatin Paclitaxel chemotherapy - Crossref

Summarized by Plex Scholar
Last Updated: 03 May 2022

* If you want to update the article please login/register

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin

Aims This review explored the role of neoadjuvant chemotherapy with bevacizumab intraperitoneal perfusion in advanced ovarian cancer. Methods In this report, 80 patients with advanced epithelial ovarian cancer who received NACT at the Central Hospital of Zhuzhou between February 2019 and October 2020 were enrolled. Results The treatment of TCB therapy successfully reduced serum CA125 and ascites volume in both serum and ascites volume. In comparison, the TCB group had significantly reduced intraoperative blood loss and reduced operating time. Patients treated with the TCB regimen had a higher surgical satisfaction rate than those treated with TCB therapy, leading to a higher surgical satisfaction rate. Conclusions The TCB's treatment of AOC as a whole is superior to the TC regimen alone, according to the authors. These findings may help with the surgical satisfaction rate, provide more effective treatment strategies to prolong progression-free survival, minimize postoperative complications, and promote surgical recovery in AOC.

Source link: https://doi.org/10.3389/fmed.2022.807377


Effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy on serum levels of HE4 and DJ-1 in patients with advanced recurrent ovarian cancer

In patients with advanced recurrent ovarian cancer who require initiation recurrent ovarian cancer, it is recommended that we investigate the effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy. Patients in the control group were treated with carboplatin mixed with paclitaxel-based intravenous chemotherapy, and patients in the observation group were treated with carboplatin mixed with paclitaxel-based IPCH. In the observation group, the response rate of the observation group was significantly higher than that of the control group; after treatment, the indexes of HE4, CD3+CD56+, and CD3+CD8+CD8+ CD3+CD8+CD8+CD8+CD8+CD4+CD56+ are all significantly reduced; finally, the indices of CD3+CD4+CD4+CD56+, CD3+CD4+CD4+CD5+CD3+CD3+CD3+CD3+CD3+CD3+CD4; CD3+CD3+CD4; the control group's of CD3+CD3+CD4+CD3+CD4+CD3+CD3+CD3+CD3+CD3+CD4+CD3+CD3+CD8+CD3+CD3+CD4+CD4+CD4+CD3+CD4+CD4+CD4+CD3+CD4+CD4+CD4+CD4+CD4+CD4+CD3+CD4+CD4+CD4+CD4+ In the control group, the prevalence of myelosuppression, nausea, and vomiting was dramatically lower than in the control group, and the incidence of total tumor metastasis in the observation group was much lower than that in the control group. Conclusions: Carboplatin and paclitaxel IPCH exerted significant inhibitory activity on HE4, DJ-1, and other serum tumor markers in patients with advanced recurrent OC, with a more prominent clinical effect, and could also minimize the risk of adverse reactions and metastasis in patients with advanced recurrent OC. In patients with advanced ovarian cancer, the effects of carboplatin and paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy have been combined.

Source link: https://doi.org/10.12669/pjms.38.4.4736


Gemcitabine and carboplatin versus gemcitabine and paclitaxel chemotherapy in cisplatin ineligible advanced-stage urothelial cancers: A prospective randomized control study.

500 Introduction: Cisplatin ineligibility in metastatic urinary bladder cancer patients poses a significant therapeutic challenge. Around 20-30% of metastatic urinary bladder cancer was found during the study. Also, there is always a desire to optimize chemotherapy options for gemcitabine combination therapy with either Paclitaxel or Carboplatin, which are both commonly used chemotherapy treatments. Methods: This was a non-funded, prospective, placebo-controlled single-center study into treatment of nave cisplatin-ineligible metastatic urothelial cancer from a tertiary care center in India. The "Arm A" received the injection and "Arm B" received the chemotherapy, respectively, and "Arm B" and "Arm B" were treated with the combination chemotherapy. According to "Arm B" vs. "Arm B" had 18. 7% vs. 25% drop out rate, respectively. According to the ORR, it was 40% vs. 88. 4%; median PFS and OS were 3. 7 vs. 14. 0 months; median PFS and OS were 3. 8 vs. 14. 0 months. However, the Gemcitabine's combination over Gemcitabine with Carboplatin yields greater ORR, OS, and lower hospitalizations for adverse event management.

Source link: https://doi.org/10.1200/jco.2022.40.6_suppl.500


Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

Despite primary debulking surgery and chemotherapy, most patients with epithelial ovarian cancer relapse. Autologous dendritic cell immunotherapy may include tumor antigens in order to promote a long-emophil response. We hypothesized that adding parallel or sequential DCVAC to CT improves clinical outcomes in patients with EOC. The trial was modified by adding Part 2 based on the interim findings of sequential DCVAC/OvCa's interim findings and to accommodate the growing interest in maintenance care in EOC. Patients with International Federation of Gynecology and Obstetrics stage III EOC, who underwent cytoreductive surgery up to three weeks before randomization and were scheduled for first-line platinum-based CT were eligible. Patients were randomly assigned to DCVAC/OvCa sequential to CT, DCVAC/OvCa sequential to CT, or CT alone in Part 1, and in Part 2 for Groups B and C. DCVAC’s patients' CD14+ monocytes were differentiated from patient's CD14+ monocytes, pulsed with two allogenic OvCa cell lines, and matured in the presence of polyinosinic:polycytidylic acid, demonstrating polyinosinic:polycytidylic acid. In 2 of 34 patients in Group A and 2 of 53 patients in Group B, the DCVAC/OvCa demonstrated a high safety profile with treatment-emergent adverse events relating to DCVAC/OvCa. Group A versus Group C was 0. 98 employees, and Group B versus Group C's HR was 0. 39 versus Group C. Patients receiving first-line treatment of EOC were shown to have a statistically significant rise in PFS in patients undergoing first-line therapy of EOC.

Source link: https://doi.org/10.1136/jitc-2021-003190


Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study

Abstract Purpose The aim of this retrospective review was to compare the effectiveness and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen with the carboplatin and nab-paclitaxel regimen in a selected population of treatment-na've, metastatic non-small cell lung cancer in a selected population. Methods Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who were first diagnosed with the atezolizumab plus carboplatin and nab-paclitaxel regimen or carboplatin and nab-paclitaxel regimen were retrospectively identified in two medical centers from 2017 to 2020. These AEs were more prevalent in the ACN group than in the CN group, but these AEs were manageable. Conclusions Atezolizumab, a drug-nave, metastatic nonsquamous PD-L1-positive NSCLC, in combination with carboplatin and nab-pactility chemotherapy may have anticancer therapy with a tolerable safety profile in selected populations of patients with treatment-nave, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab.

Source link: https://doi.org/10.1007/s00432-021-03873-3


A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Arm A's 1-year PFS was 47 percent, which was higher than the previous control 1-year PFS of 15%. On Arm B, there was an overall survival of patients treated on Arm A of 15. 9 months and 13. 9 months. This is the first report to show a significant improvement in PFS with the use of metformin in this patient population, and it is a measure of safety for metformin in advanced NSCLC, according to the authors. This is the first trial in nondiabetic advanced non-small cell lung cancer patients with metformin in lieu of standard first-line chemotherapy, according to the authors' reports. Metformin, which is well tolerated and widely available, is a drug that should be investigated further in the lung cancer research literature.

Source link: https://doi.org/10.1634/theoncologist.2017-0465

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions